SNY vs TKNO: fair value comparison
Sanofi and Alpha Teknova, Inc. · Updated 2026-10-19
SNY reports in EUR, so no same-currency fair-value verdict is published for it. TKNO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SNY currently ranks higher by quality score.
| SNY | TKNO | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $40.67 | $7.08 |
| 12-month range | $39.12–$52.34 | $1.99–$9.33 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #122 of 301 Healthcare | #123 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: SNY fair value analysis · TKNO fair value analysis